December 28, 2020 7:55am

Another holiday short-week and final trading week of 2020

What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

A pre-open briefing on what you need to know in the session ahead!

Dow futures are UP +0.52% (+157 points), S&P futures are UP +0.67% (+25 points) and NASDAQ futures are UP +0.74% (+94 points)


Futures project a positive open on Monday as President Trump finally signed an economic aid/relief bill;

European markets rose as traders reacted to Brexit and U.S. aid development;

  • The Brexit agreement, sealed after markets closed on Dec. 24, still needs to be approved this week by U.K. lawmakers before the Dec. 31 deadline.

Asia Pacific markets were mixed after Hong Kong dived when shares of Alibaba got caught-up in political acrobatics while markets in Australia and New Zealand are closed on Monday for a holiday.



President Trump unexpectedly signed an economic relief bill after holding-out …

Markets are coming off a quiet holiday week where the major averages posted flat returns; the S&P 500 fell 0.2%, the Dow eked out a 0.1% gain for the same period.  

For the year-to-date, the S&P 500 gained 14.6% year to date, the Dow 5.8% with the Nasdaq soaring 42.7% during this Covid-19 pandemic period.


Thursday’s afternoon’s recap: RegMed Investors’ (RMi) closing bell: “algorithms took their toll giving coal to share pricing to burn most upsides for this session and week; …

  • The Nasdaq closed UP +33.62 points (+0.26%);
  • The IBB closed down -0.76% and XBI closed down -0.82%;
  • Sector volume was ANEMIC with 1 of the 8-upside having higher than the 3-month average volume with the increased volume of 3 of 25-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -1.85 points or -7.94% at 21.46
  • Thursday’s percentage (%) of the 8-upside were +0.42% (VCEL) to +3.15% (PSTI) while the 25-downside ranges from -0.0.12% (RGNX) to -13.79% (BSTG);


  • Q4’s December, so far: 1 holiday, 2 neutral, 4 negative and 12 positive closes
  • Q4’s November: 16 positive and 3 negative closes
  • Q4’s October: 1 neutral, 11 positives with 1 negative closes

Q3: July through September: 1 neutral, 28 positive and 34 negative closes with 2 holidays


Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed down -$0.20 to $1.25 with 16,622 shares traded after Wednesday’s +$0.20 to $1.45 with 159 shares traded, Tuesday’s -$0.20 to $1.25 with 1,398 shares traded and last Monday’s +$0.09 to $1.45 with 7,282 shares traded.  Continuing the questions …

  • Question#1: WHAT is the “game plan” for the nine (9)-month-old IND to start clinical trials?
  • Question#2: DOES RMS US, their accounting “affirm” the status of this company as a “going concern”. A rent-a-CFO and NO AUDIT board members MUST make them question the status – WHY NOT?
  • Question#3: WILL RMS US define their OPINION of the on-going “gap” between an IND approval and a clinical trial initiation a publicly-traded company in their year-end review?


The BOTTOM LINE: Investors should be celebrating the share pricing uprisings but, the yearend approaches and profits should be “pulled” from many equities within a stem, cell and gene therapy holdings.

Reiterating, the remainder of the 2020 will be choppy trading and the mostly upside results of previous months should cause many to relive their portfolio of risk and add new positions.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.